Compass Therapeutics, Inc.

CMPX

Compass Therapeutics, Inc.

CMPX

Insider Sentiment (TTM):

Last Purchase:2026-04-29Last Sale:2025-04-09Shares Purchased (TTM):40,000Shares Sold (TTM):0

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:172,032,334Shares Outstanding:186,400,000Institutional Ownership Pct.:92.29%

Earnings Market Reaction:

Filing Date:2026-08-06Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Cash And Cash Equivalents At Carrying Value	35	55	31	46	23	41	43	19	19	43	24	30
Assets Current
Assets Current	181	196	210	221	106	124	133	141	154	159	154	167
Marketable Securities Current	144	140	178	174	78	72	83	99	127	133	128	133
Prepaid Expense And Other Assets Current	1	1	1	1	5	12	6	6	7	2	1	3
Property Plant And Equipment Net	0	0	0	0	0	0	0	0	1	1	1	1
Operating Lease Right Of Use Asset	8	9	9	9	10	7	7	7	1	1	2	2
Restricted Cash	1	1	1	1	1	1	1	-	-	-	-	-
Other Assets Noncurrent	-	-	-	-	-	-	1	1	0	0	0	0
Assets	190	205	220	231	117	131	140	149	156	161	157	170
Accounts Payable Current	3	1	2	3	3	2	2	1	1	1	4	2
Accrued Liabilities Current	12	8	11	9	11	13	6	3	7	2	3	6
Liabilities Current
Liabilities Current	16	10	14	12	14	15	9	4	10	4	8	9
Operating Lease Liability Current	2	1	1	1	0	0	0	1	1	1	1	1
Operating Lease Liability Noncurrent	8	8	9	9	10	6	6	6	0	0	1	1
Liabilities	24	19	23	22	23	21	15	11	10	4	8	10
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Stockholders Equity
Additional Paid In Capital Common Stock	641	636	628	625	494	491	490	488	485	483	464	462
Stockholders Equity	166	186	197	210	93	110	125	138	146	157	149	160
Accumulated Other Comprehensive Income Loss Net Of…	-0	-0	0	0	0	0	0	0	-0	-0	0	-0
Retained Earnings Accumulated Deficit	-475	-449	-431	-415	-401	-381	-365	-350	-339	-326	-315	-302
Liabilities And Stockholders Equity	190	205	220	231	117	131	140	149	156	161	157	170
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	300	300	300	300	300	300	300	300	300	300	300	300
Shares Outstanding	180	180	178	178	138	138	138	138	138	138	128	127
Common Stock Shares Issued	180	180	178	178	138	138	138	138	138	138	128	127

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	22.05%	6.67%	6.15%	-	-	-	-	-	-	-	-	-
2025	17.98%	43.82%	78.65%	2.99%	10.78%	11.98%	51.83%	35.34%	54.45%	-5.79%	-9.04%	-62.57%
2024	-16.03%	-48.72%	-36.15%	26.55%	70.80%	50.44%	-7.26%	-12.85%	79.89%	-20.89%	-40.07%	-28.08%
2023	-	-	-	-	-	-	4.97%	-3.11%	-13.66%	-27.68%	-28.57%	-41.52%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	11.22	19.04	15.02	17.82	7.66	8.33	14.96	31.84	16.15	40.74	19.73	18.26
Quick Ratio	11.15	18.94	14.96	17.72	7.28	7.56	14.28	30.54	15.38	40.14	19.54	17.94
Working Capital	164.76M	185.41M	195.85M	208.71M	92.34M	109.25M	123.88M	136.71M	144.04M	154.72M	146.08M	157.46M
Leverage & Debt
Debt to Equity	0.15	0.10	0.12	0.10	0.25	0.19	0.12	0.08	0.07	0.03	0.06	0.06
Debt Ratio	0.13	0.09	0.10	0.09	0.20	0.16	0.11	0.07	0.06	0.03	0.05	0.06
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.01	0.01	0.01	0.01	0.00	0.00	0.00
Per Share Metrics
Diluted EPS TTM	-	-	-	-	-	-0.40	-0.36	-0.35	-	-	-	-
Free Cash Flow Per Share TTM	-0.28	-0.29	-0.31	-0.19	-0.23	-0.32	-0.33	-0.35	-0.31	-0.31	-0.32	-0.31
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-	-	-	-	-	-7,273.06%	-6,661.76%	-6,522.71%	-6,485.88%	-	-	-
Net Profit Margin TTM	-	-	-	-	-	-6,496.59%	-5,808.82%	-5,618.71%	-5,557.88%	-	-	-
Growth Metrics
Net Revenue Growth (1Y)	-	-100.00%	-100.00%	-100.00%	-100.00%	-	-	-	-	-	-	-
Net Income Growth (1Y)	18.41%	23.45%	34.66%	37.78%	31.29%	21.51%	16.19%	17.42%	10.68%	13.89%	8.33%	0.15%
EPS Growth (1Y)	-12.34%	-8.44%	17.32%	12.32%	30.64%	20.08%	7.43%	8.75%	1.94%	5.36%	-10.29%	-20.61%
Valuation Metrics
P/E TTM	-5.57	-14.46	-12.74	-8.98	-5.80	-4.76	-4.03	-5.30	-2.91	-5.95	-4.66	-6.17
P/B TTM	2.46	5.29	4.30	2.82	3.86	2.38	1.59	1.83	0.94	1.72	1.33	1.57
P/S TTM	-	-	-	-	-	309.00	234.36	297.84	161.87	-	-	-
Market Cap	409.09M	986.06M	846.82M	590.74M	359.53M	262.65M	199.21M	253.16M	137.59M	270.48M	198.16M	251.03M
Enterprise Value	373.63M	930.32M	816.18M	544.53M	336.68M	221.60M	155.16M	233.76M	118.19M	227.00M	173.93M	220.60M
Calculated Values
Free Cash Flow TTM	-52.25M	-53.33M	-49.20M	-31.89M	-32.13M	-44.24M	-44.90M	-48.10M	-42.94M	-42.31M	-40.65M	-38.98M
Net Debt	-35.45M	-55.74M	-30.64M	-46.21M	-22.86M	-41.05M	-44.05M	-19.40M	-19.40M	-43.48M	-24.23M	-30.43M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-04-29Purchase

Owner: Anderman, Jonathan

Title: General Counsel

Shares: 25,000

Price/Share: $1.89

Value: $47,250.00

Shares Owned: 196,000

Relationship: Officer

Ownership: Direct

2026-04-29Purchase

Owner: Lerner, Neil

Title: Chief Accounting Officer

Shares: 15,000

Price/Share: $1.89

Value: $28,350.00

Shares Owned: 397,500

Relationship: Officer

Ownership: Direct

2025-05-27Purchase

Owner: Schuetz, Thomas J.

Title: CHIEF EXECUTIVE OFFICER

Shares: 10,000

Price/Share: $2.11

Value: $21,100.00

Shares Owned: 6,480,825

Relationship: Director,Officer

Ownership: Direct

2025-04-09Sale

Owner: Orbimed, Capital Gp Vi Ll…

Title: -

Shares: 3,571,428

Price/Share: $1.59

Value: $5,678,570.52

Shares Owned: -

Relationship: Director,TenPercentOwner

Ownership: Indirect

2025-04-09Sale

Owner: Gordon, Carl L

Title: -

Shares: 3,571,428

Price/Share: $1.59

Value: $5,678,570.52

Shares Owned: -

Relationship: Director,TenPercentOwner

Ownership: Indirect

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-04-29	Anderman, Jonathan	Officer	General Counsel	Direct	Purchase	25,000	1.89	$47,250.00	196,000	4/A
2026-04-29	Lerner, Neil	Officer	Chief Accounting Officer	Direct	Purchase	15,000	1.89	$28,350.00	397,500	4/A
2025-05-27	Schuetz, Thomas J.	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Purchase	10,000	2.11	$21,100.00	6,480,825	4
2025-04-09	Orbimed, Capital Gp Vi Ll…	Director,TenPercentOwner	-	Indirect	Sale	3,571,428	1.59	$5,678,570.52	0	4
2025-04-09	Gordon, Carl L	Director,TenPercentOwner	-	Indirect	Sale	3,571,428	1.59	$5,678,570.52	0	4
2025-04-07	Lerner, Neil	Officer	CHIEF ACCOUNTING OFFICER	Direct	Purchase	20,000	1.42	$28,400.00	320,000	4
2025-04-07	Anderman, Jonathan	Officer	Gen Counsel & Corporate Sec	Direct	Purchase	20,000	1.54	$30,800.00	21,000	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

92.29%

Inst. Shares: 172,032,334

Shares Outstanding: 186,400,000

2025-12-31

104.32%

Inst. Shares: 164,504,751

Shares Outstanding: 157,695,000

2025-09-30

89.35%

Inst. Shares: 150,810,097

Shares Outstanding: 168,782,000

2025-06-30

77.73%

Inst. Shares: 107,481,568

Shares Outstanding: 138,282,000

2025-03-31

77.36%

Inst. Shares: 106,938,991

Shares Outstanding: 138,236,000

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	172,032,334	186,400,000	92.29%
2025-12-31	164,504,751	157,695,000	104.32%
2025-09-30	150,810,097	168,782,000	89.35%
2025-06-30	107,481,568	138,282,000	77.73%
2025-03-31	106,938,991	138,236,000	77.36%
2024-12-31	100,644,185	137,384,000	73.26%
2024-09-30	91,798,761	137,589,000	66.72%
2024-06-30	92,446,127	137,589,000	67.19%
2024-03-31	94,288,496	136,608,000	69.02%
2023-12-31	85,595,406	127,027,000	67.38%
2023-09-30	89,482,328	127,424,000	70.22%
2023-06-30	90,253,557	126,729,000	71.22%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Compass Therapeutics, Inc. (CMPX) — SEC Financial Statements & Analysis

Compass Therapeutics, Inc. (CMPX) is a biological products, (no diagnostic substances) company, incorporated in DE. Compass Therapeutics, Inc. trades on Nasdaq as: CMPX. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Compass Therapeutics, Inc. reported a -100.00% year-over-year revenue growth, a Debt-to-Equity ratio of 0.15x, a Price-to-Sales (P/S) ratio of 309.00x (TTM), a Price-to-Book (P/B) ratio of 2.46x (TTM), at a market cap of $409.09M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -100.00%
Debt To Equity: 0.15x
P/S TTM: 309.00x
P/B TTM: 2.46x
Market Cap: $409.09M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Compass Therapeutics, Inc. in?

Compass Therapeutics, Inc. (CMPX) operates in the Biological Products, (No Diagnostic Substances) industry.

What is CMPX's market cap?

Compass Therapeutics, Inc. (CMPX) has a market capitalization of $409.09M as of 2026-06-30.

What exchange does CMPX trade on?

Compass Therapeutics, Inc. (CMPX) trades on the Nasdaq.

Where is Compass Therapeutics, Inc. incorporated?

Compass Therapeutics, Inc. is incorporated in DE.